Cover Image

PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Daniel Q. Huang, Zhongjie Zhang, Rajkumar Dorajoo, Chiea Chuen Khor, Yen Thi‐Hai Pham, Renwei Wang, Jaideep Behari, Jian‐Min Yuan, Woon‐Puay Koh, Hung N. Luu
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
by: Daniel Q. Huang, et al.
Published: (2026)

Editorial: Understanding the Role of the Alpha‐1 Pi* MZ Genotype in the Development of Hepatocellular Carcinoma for Patients With ACLD
by: Kaitlyn Carlson, et al.
Published: (2026)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study
by: Ahmed Helmy
Published: (2025)

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort
by: Seogsong Jeong, et al.
Published: (2026)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
by: Gamal Shiha, et al.
Published: (2025)

Editorial: Flipping the Script—Higher Risk of Hepatocellular Carcinoma With Tenofovir Compared to Entecavir in a French Population‐Based Cohort
by: Ariel Lee, et al.
Published: (2025)

Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort
by: Najib Ben Khaled, et al.
Published: (2025)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
by: Jia‐Ling Wu, et al.
Published: (2025)

Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
by: Soon Sun Kim, et al.
Published: (2025)

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
by: Vincent Haghnejad, et al.
Published: (2025)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
by: Kanghee Park, et al.
Published: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
by: Zhejin Shi, et al.
Published: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
by: Darren Jun Hao Tan, et al.
Published: (2024)

Very Early‐Stage Detection Is Associated With Improved Survival in Patients With Unifocal Hepatocellular Carcinoma
by: Thomas Hunold, et al.
Published: (2025)

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma
by: Rong Ding, et al.
Published: (2026)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
by: Dong Hyun Kim, et al.
Published: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
by: Sifu Yang
Published: (2025)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
by: Suzanne Sharpton, et al.
Published: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
by: Mohammad Saeid Rezaee‐Zavareh, et al.
Published: (2026)

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)
by: Marco Sanduzzi‐Zamparelli, et al.
Published: (2026)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
by: Subin Heo, et al.
Published: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
by: Jiwon Yang, et al.
Published: (2025)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
by: Elisa Pinto, et al.
Published: (2026)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
by: L. Aceituno, et al.
Published: (2026)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
by: Jonggi Choi
Published: (2025)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
by: Yuanyan Sun, et al.
Published: (2026)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar?
by: Danny Con
Published: (2025)

Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early‐Stage Hepatocellular Carcinoma
by: Ashwini Arvind, et al.
Published: (2025)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
by: You‐Jian Xu, et al.
Published: (2024)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
by: Lesley A. Patmore, et al.
Published: (2025)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
by: Kuo‐Cheng Wu, et al.
Published: (2024)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
by: Xiao‐Dong Zhou, et al.
Published: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
by: Shuaibing Ying, et al.
Published: (2026)

Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease
by: Rosellina M. Mancina, et al.
Published: (2025)

Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study
by: Maria Mironova, et al.
Published: (2024)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
by: Pardhu Bharath Neelam, et al.
Published: (2025)

Correction to ‘Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon’
Published: (2025)

Retrospective Cohort Study: Scope for Improvement—Barriers to Post‐Polypectomy Surveillance in the Integrated Technologies for Improved Polyp Surveillance Cohort
by: Charlotte Mathews, et al.
Published: (2025)